Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: Potential for consolidation in ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cisplatin
  • Ovarian Neoplasms
  • Topotecan

abstract

  • Topotecan IP for 3-5 days is tolerable; occasionally, myelosuppression is dose-limiting. Topotecan 1.25 mg (days 1-3) with IP cisplatin 50 mg/m(2) (day 1) is a regimen suitable for consolidation in phase 3 trials.

publication date

  • August 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-010-1510-y

PubMed ID

  • 21069334

Additional Document Info

start page

  • 457

end page

  • 63

volume

  • 68

number

  • 2